Skip to content
ClearheadLab
Explore

Provider & product review

Strut Health NAD+ Review: The Page Describes the Wrong Molecule

Strut sells a 500 mg NAD+ injection from $149 and prints the dose — then explains NAD+ as a peptide that signals the pituitary. It isn't one.

Written with care by Nadia BrooksUpdated

Our verdict

Strut Health may interest buyers who want a published injection strength: its public NAD+ page advertises a 500 mg product at 200 mg/mL starting at $149. The advertised amount does not by itself establish the supplied period, auto-refill conditions or one-time purchase price. Confirm those details and the dispensing pharmacy before enrolling.

A regulatory disclosure matters here: FDA issued a warning letter to Strut Health in February 2026 concerning compounded semaglutide and tirzepatide advertising. This is a finding about those claims, not proof that every NAD+ product is defective. Read the letter and the discussion below before deciding.5 The clinical evidence discussed here does not establish a cognitive benefit from NAD+ injections.

On this page

What Strut is, and what it charges

Strut Health, LLC operates out of 701 Commerce Street in Dallas, Texas, with Simal Patel, MD named as chief executive — an individual named at all, which is rarer in this category than it should be. A licensed clinician reviews an online intake behind a Persona identity check, and the medication is compounded and shipped.

The catalog around NAD+ is unusually shaped. Sermorelin ships both as an injection and as an oral lozenge, which very few operators offer. Strut also sells its own capsule supplements, PeptideVite and StrutVite. What it does not sell is a second NAD+ route, glutathione, methylene blue, or a standalone B-12 injection — so if you came for a nasal spray, this is not the shop.

What Strut publishes, and what it leaves out

ProductRouteAuto-refillOne-off 30 days
NAD+ 500 mgSub-Q injectionFrom $149; confirm supplyNot published
Sermorelin 9 mgSub-Q injection$119/moNot published
Sermorelin, 30 lozengesSublingual$99/moNot published
Tirzepatide (weight loss)Injection$199/mo$325 — a 63% premium
Every advertised rate is an auto-refill rate. Strut publishes a one-off price for only two products — and where it does, the gap is much larger than the saving badge implies.

The auto-refill structure behind the headline

Every headline figure Strut advertises is an auto-refill rate — the price if you leave a recurring subscription running. That is a normal enough arrangement, and it is not hidden. The problem is what sits on the other side of it: Strut publishes the one-off, non-auto-refill price for almost nothing.

For NAD+, the one-off price is not published at all. We know the size the gap can reach because Strut does publish it in two places on its weight-loss line, and it is large: injectable tirzepatide is $199 on auto-refill and $325 as a one-off, a 63% premium for the same 30-day supply, under a badge advertising a 14% saving that does not reconcile with either number.

Do not infer a NAD+ one-time purchase price from another product. Ask Strut for a quote for the selected prescription, supplied period and refill choice.

The other structural note is that Strut's newer `/peptides`, `/testosterone` and `/weight-loss` templates ship with no prices on them at all — so which URL you land on decides whether you see a figure.

The FDA warning letter

FDA issued a warning letter to Strut Health, LLC dba Strut in February 2026. The FDA index reviewed here did not display a closeout entry; that is the scope of the status observation, not a determination about every product or later corrective action.5

It is addressed to "Strut Health, LLC dba Strut" and was issued in February 2026 by the Center for Drug Evaluation and Research. In the FDA's public warning-letter index, the close-out column for it is empty, which means no close-out letter has been issued. The letter's own recipient block names Strut's chief executive and its Dallas address and states that FDA reviewed struthealth.com — the same site this review is about, so this is the company and not a name collision.

We are not going to restate what it alleges. That is the FDA's document to characterize, and paraphrasing an enforcement action on a page that earns a commission from the company would turn a public record into an accusation of ours. The entity string above is the search term: type it into the FDA's warning-letter database and read the letter itself.

One thing we will state, because it is an observation about the website rather than a characterization of the letter: Strut makes no mention of it anywhere on its own site.

A letter does not remove a provider from our ranking and never has. Other companies we rank carry one and stay ranked with the same notice printed on every surface that sells them, paid and unpaid alike. What it does is create an obligation on us to say so before you press anything.

Where Strut is genuinely better than its neighbors

Check eligibility for your prescription. Strut's previously reviewed state interface and FAQ agreed on 49 states plus Washington DC and Puerto Rico, excluding Arkansas. That was a comparison of the company's public information, not independent verification of licensing or present eligibility. Confirm your address and prescribed route before paying.

The dose is published. 500 mg, stated, beside the price. Compare that with the several providers we rank whose every figure reads "starting at" with no strength anywhere — which makes a per-milligram comparison impossible and is one of the recurring problems with how NAD+ dosing is presented.

Checked against the source, not the sales page

Questions to resolve before paying

  • Previously reviewed public state information listed 49 states plus DC and Puerto Rico, excluding Arkansas. Confirm present eligibility for your prescription.
  • The NAD+ dose is published — 500 mg — which most of the field will not do.
  • No compounding pharmacy is named, and the refund policy was last modified in September 2021.
  • FDA issued a February 2026 warning letter about compounded GLP-1 advertising. The reviewed index did not display a closeout; this is not a finding that every NAD+ product is defective.
  • The NAD+ page calls NAD+ “a peptide that signals your own pituitary gland”. That is sermorelin's description, not NAD+'s.
Public state information can help you ask about eligibility; it does not independently verify prescribing licenses or availability for your order.

Where it is worse

No compounding pharmacy is named. "U.S. compounding pharmacies" is the whole disclosure. Several companies we rank name theirs — one names seven — and naming one is what makes it checkable.

Refund and cancellation terms. The previously reviewed policy said no refunds after medication leaves the pharmacy and required 48 hours notice for subscription cancellation. Confirm the policy that applies to your order before paying.

"Medical Necessity Required" appears on every GLP-1 with no published criteria for what would satisfy it.

And the NAD+ explanation is wrong. We have come back to it deliberately, because of everything on this page it is the thing most likely to change what a reader believes they are buying. A company that has not noticed its own product description is about a different molecule has not read its own product description.

The evidence, which is the same for every provider we rank

Setting aside how Strut describes it, the underlying position on this site does not move for a paid partner. No rigorous human trial shows that injected NAD+ improves cognition, focus or energy. In older adults with mild cognitive impairment, oral nicotinamide riboside raised NAD+ levels and did not improve cognition versus placebo1; a second randomized trial in subjective cognitive decline and mild cognitive impairment found no cognitive benefit either2; and the only human data on a parenteral route is a pilot that tracked NAD+ metabolites through a six-hour infusion and measured no cognitive outcome at all3.

The full picture is in our review of what the NAD+ evidence supports and what it does not. The compounded preparation Strut dispenses is also not an FDA-approved product, and a compounded drug is not a generic equivalent of an approved one4 — which is worth holding beside the fact that its own page describes the molecule incorrectly.

Who it is for

If a published injection strength matters to you, Strut provides one. Its current starting $149 headline still needs a confirmed supply period and renewal schedule; a one-off purchase should be quoted separately rather than inferred from another product.

And if you are choosing partly on whether a company understands the thing it sells, the NAD+ page is the evidence you have. It says the product is a peptide that signals your pituitary gland. We wrote a whole piece on how NAD+ is marketed against how nootropics are marketed, and the pattern is the same one: the more confidently a page explains the mechanism, the less often the explanation is checked.

The bottom line

Strut publishes a 500 mg NAD+ injection starting at $149. Confirm the supply period, auto-refill and one-time price, dispensing pharmacy and refund terms. Its February 2026 FDA warning letter concerns compounded GLP-1 advertising and belongs in the decision alongside the limitations of the NAD+ evidence.5

A few gentle questions

How much does Strut Health NAD+ cost?

A 500 mg subcutaneous injection is advertised starting at $149; supplied period must be confirmed, with the dose published beside the figure. Confirm the supplied period and auto-refill conditions; the headline alone does not establish them. Strut does not publish a one-off, non-auto-refill price for NAD+ anywhere, so what a single order costs is not knowable from the site.

Is $149 the price if I cancel auto-refill?

Unknown, and we will not estimate it. Strut publishes a one-off 30-day price for only two products. On injectable tirzepatide the one-off is $325 against a $199 auto-refill rate — a 63% premium — under a badge advertising a 14% saving that reconciles with neither figure. That is the size the gap can reach; it is not a NAD+ number and must not be treated as one.

Does Strut Health have an FDA warning letter?

Yes. FDA issued a February 2026 letter to Strut Health, LLC dba Strut concerning compounded semaglutide and tirzepatide advertising. The reviewed FDA index did not display a closeout entry. Read the actual letter; it is not a determination that every NAD+ product is defective.

Is NAD+ a peptide?

No. NAD+ is a coenzyme — a nucleotide every cell uses in the reactions that release energy from food. It is not a peptide and it does not act on the pituitary gland. Strut's own NAD+ page says it is “a peptide that signals your own pituitary gland”, which is the description of sermorelin, a different product Strut sells on a different page. We flag it because that sentence is the only account of the product most buyers will read.

Which states does Strut Health serve?

A previous comparison of the public state interface and FAQ listed 49 states plus DC and Puerto Rico, excluding Arkansas. That observation does not independently verify current licensing or eligibility; ask before paying.

Which pharmacy compounds Strut's NAD+?

It does not say. The disclosure is “U.S. compounding pharmacies” and no facility is named, so there is nothing a reader can check. Several companies we rank do name theirs, and naming one is what makes the claim verifiable.

Does Strut sell a nasal NAD+ spray?

No. The injection is the only NAD+ route it sells. There is also no glutathione, no methylene blue and no standalone B-12 injection. It does sell sermorelin in two routes — an injection and an oral lozenge — which is unusual, and its own supplements.

Is NAD+ proven to help brain fog or focus?

No, and a commission does not change that. No rigorous human trial shows that injected NAD+ improves cognition, focus or energy. The two randomized trials of oral NAD+ precursors that measured cognition found no benefit versus placebo, and the only human data on a parenteral route measured no cognitive outcome at all. The compounded product sold here is also not FDA-approved.

Where this comes from

  1. Orr ME, Kotkowski E, Ramirez P, Bair-Kelps D, Liu Q, Brenner C, et al. (2024). A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment. GeroScience. 2024;46(1):665-682. https://pubmed.ncbi.nlm.nih.gov/37994989/
  2. Wu CY, Kupferschmid AC, Chen L, McManus AJ, Kivisäkk P, Galler JA, et al. (2025). Cognitive and Alzheimer's disease biomarker effects of oral nicotinamide riboside (NR) supplementation in older adults with subjective cognitive decline and mild cognitive impairment. Alzheimers Dement (N Y). 2025;11(1):e70023. https://pubmed.ncbi.nlm.nih.gov/39817194/
  3. Grant R, Berg J, Mestayer R, Braidy N, Bennett J, Broom S, et al. (2019). A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+. Frontiers in Aging Neuroscience. 2019;11:257. https://pubmed.ncbi.nlm.nih.gov/31572171/
  4. U.S. Food and Drug Administration (2026). Compounding and the FDA: Questions and Answers. FDA, Human Drug Compounding. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
  5. U.S. Food and Drug Administration (2026). Strut Health, LLC dba Strut — warning letter, February 20, 2026 (MARCS-CMS 721448). FDA. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.